This database contains 32 studies, archived under the term: "radionuclide imaging"
Click here to filter this large number of results.
Perseverative errors on the Wisconsin Card Sorting Test and brain perfusion imaging in mild Alzheimer’s disease
Terada, Seishi,
Sato, Shuhei,
Honda, Hajime,
Kishimoto, Yuki,
Takeda, Naoya,
Oshima, Etsuko,
Yokota, Osamu,
Uchitomi, Yosuke
Background: The Wisconsin Card Sorting Test (WCST) has long been used to investigate deficits in executive function in humans. The majority of studies investigating deficient WCST performance focused on the number of categories achieved (CA) and the number of perseverative errors of the Nelson type (PEN). However, there is insufficient evidence that these two measures […]
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, Michael,
Almkvist, Ove,
Axelman, Karin,
Stefanova, Elka,
Wall, Anders,
Westman, Eric,
Långström, Bengt,
Lannfelt, Lars,
Graff, Caroline,
Nordberg, Agneta
Six young related pre-symptomatic carriers of a His163Tyr mutation in the presenilin 1 gene who will develop early onset familial Alzheimer’s disease (eoFAD), and a control group of 23 non-carriers underwent (18)F-fluorodeoxyglucose positron emission tomography (FDG PET). The mutation carriers were followed-up after 2 years. Multivariate analysis showed clear separation of carriers from non-carriers on […]
Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus
Rinne, Juha O.,
Frantzen, Janek,
Leinonen, Ville,
Lonnrot, Kimmo,
Laakso, Aki,
Virtanen, Kirsi A.,
Solin, Olof,
Kotkansalo, Anna,
Koivisto, Anne,
Sajanti, Juha,
Karppinen, Atte,
Lehto, Hanna,
Rummukainen, Jaana,
Buckley, Chris,
Smith, Adrian,
Jones, Paul A.,
Sherwin, Paul,
Farrar, Gill,
McLain, Richard,
Kailajarvi, Marita,
Grachev, Igor D.
Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical region biopsy site.; Methods: Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective [(18)F]flutemetamol PET and subsequent frontal cortical […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]
18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
O'Brien, J. T.,
Firbank, M. J.,
Davison, C.,
Barnett, N.,
Bamford, C.,
Donaldson, C.,
Olsen, K.,
Herholz, K.,
Williams, D.,
Lloyd, J.
Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]
Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy
Miyoshi, F.,
Ogawa, T.,
Kitao, S.- i.,
Kitayama, M.,
Shinohara, Y.,
Takasugi, M.,
Fujii, S.,
Kaminou, T.
Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late […]
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline
Grundman, Michael,
Pontecorvo, Michael J.,
Salloway, Stephen P.,
Doraiswamy, P. Murali,
Fleisher, Adam S.,
Sadowsky, Carl H.,
Nair, Anil K.,
Siderowf, Andrew,
Lu, Ming,
Arora, Anupa K.,
Agbulos, Abigail,
Flitter, Matthew L.,
Krautkramer, Michael J.,
Sarsour, Khaled,
Skovronsky, Daniel M.,
Mintun, Mark A.
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]